TLR9 and neoplasm: [59], illustrates that the intravenous administration of the TLR9 agonist GNKG168 to pediatric ALL patients in remission triggers immunological changes, leading to a notable enhancement in immune responses characterized by increased T and B cell production, improving the ability of tumor recognition by immune cells [29, 59], as indicated in Table 2.